A major new clinical trial seeks to determine whether HIV-infected individuals with no symptoms have less risk of developing AIDS or related illnesses if they begin taking treatments sooner rather than later.
SPH professor Jim Neaton will lead the trial, which involves 4,000 HIV-infected participants at more than 250 clinical sites in 36 countries. Participants will be followed for up to five years.
The trial is the latest from the International Network for Strategic Initiatives in Global HIV Trials (INSIGHT), the world’s largest HIV/AIDS clinical trial network, funded by the NIH’s National Institute of Allergy and Infectious Diseases.
Read more in Advances Magazine.